There’s an enzyme in your fat cells called NNMT. Its job, essentially, is to slow down your metabolism — it degrades a methyl donor that cells need to produce NAD+, the coenzyme that powers cellular energy production. More NNMT activity → less NAD+ → slower metabolism → more fat storage. It’s a brake pedal on your metabolic engine.
5-Amino-1MQ blocks that brake. And the published research on what happens next is why this compound has become one of the most discussed molecules in metabolic research.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
What Is NNMT (And Why Should You Care)?
Nicotinamide N-methyltransferase (NNMT) is an enzyme that methylates nicotinamide (vitamin B3) — converting it to 1-methylnicotinamide and consuming SAM (S-adenosyl methionine) in the process. Both of those reactions have metabolic consequences:
- Nicotinamide depletion: Nicotinamide is a precursor for NAD+ synthesis through the salvage pathway. When NNMT methylates it, that nicotinamide is diverted away from NAD+ production. Less NAD+ → impaired energy metabolism, reduced sirtuin activity, and compromised mitochondrial function.
- SAM depletion: SAM is the universal methyl donor for epigenetic modifications, neurotransmitter synthesis, and other methylation reactions. NNMT’s consumption of SAM has downstream effects on gene expression and cellular regulation.
Here’s the kicker: NNMT is overexpressed in obesity. Fat tissue from obese individuals shows significantly higher NNMT levels than lean individuals. This creates a vicious cycle: more fat → more NNMT → less NAD+ → worse metabolism → more fat.
What 5-Amino-1MQ Does
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor — not a peptide, technically, but a quinolinium derivative that’s earned its place in the metabolic research conversation alongside NAD+ and MOTS-c because of where it acts in the same pathway.
By blocking NNMT, 5-Amino-1MQ does the opposite of what the enzyme does:
- More nicotinamide available → more NAD+ synthesis → improved cellular energy production
- More SAM available → improved methylation reactions → better epigenetic regulation
- Breaks the obesity cycle → less NNMT activity → improved metabolic function in adipose tissue
The Published Research
Fat Cell Metabolism
Neelakantan et al. (2019) published the key preclinical study in Biochemical Pharmacology. In adipocyte cell cultures, 5-Amino-1MQ treatment:
- Reduced NNMT activity in a dose-dependent manner
- Increased intracellular NAD+ levels
- Reduced lipid accumulation in differentiating adipocytes
- Shifted gene expression toward a more metabolically active profile
The effect was specific to NNMT — other methyltransferases were not significantly affected at the concentrations used, suggesting good target selectivity.
Diet-Induced Obesity Models
In mouse models of diet-induced obesity, NNMT inhibition (through various approaches including 5-Amino-1MQ) was associated with:
- Reduced body weight gain without changes in food intake (metabolic, not appetite-driven)
- Reduced white adipose tissue mass
- Improved glucose tolerance
- Increased energy expenditure
The “without changes in food intake” part is important. The animals weren’t eating less — they were metabolizing more efficiently. That’s a fundamentally different mechanism from appetite suppressants or GLP-1 agonists.
The NAD+ Connection
This is where 5-Amino-1MQ connects to the broader NAD+ research landscape. NNMT is essentially an NAD+ drain — it removes the precursor (nicotinamide) that cells need to rebuild NAD+ through the salvage pathway. Blocking NNMT is like plugging a leak in the NAD+ supply chain.
This positions 5-Amino-1MQ as a complementary approach to direct NAD+ supplementation: instead of flooding the system with more NAD+ (or its precursors NMN/NR), you stop the enzyme that’s draining the precursor pool. Different strategy, same metabolic endpoint.
What 5-Amino-1MQ Is NOT
- Not a peptide — it’s a small molecule (quinolinium derivative). It’s in the peptide research catalog because it acts on the same metabolic pathways.
- Not an appetite suppressant — the metabolic effects occur without reducing food intake.
- Not a direct NAD+ supplement — it works upstream, preserving the precursor rather than providing NAD+ directly.
Product Specifications
- Chemical Name: 5-amino-1-methylquinolinium
- Molecular Weight: 173.21 g/mol
- CAS Number: 42816-36-4
- Physical Form: Lyophilized powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Soluble in water
Key References
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of NNMT. Biochem Pharmacol. 2019;168:1-11.
- Kraus D, et al. NNMT knockdown in adipose tissue promotes thermogenesis. Nature. 2014;508:258-262.
- Pissios P. NNMT: a critical modulator of energy homeostasis. Trends Endocrinol Metab. 2017;28(5):340-353.
Browse 5-Amino-1MQ with verified COA from Janoshik Analytical. For related metabolic research, explore NAD+ 500mg, MOTS-c, and our Metabolic Research category.